Cargando…
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
The Hepatocyte growth factor (HGF)—mesenchymal-epithelial transition (MET) pathway is deregulated in several cancers and is associated with aggressive phenotype and worse prognosis. MET, a tyrosine kinase receptor activated by HGF, plays a physiological role in embryogenesis, promoting cell growth,...
Autores principales: | Della Corte, Carminia Maria, Fasano, Morena, Papaccio, Federica, Ciardiello, Fortunato, Morgillo, Floriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344276/ https://www.ncbi.nlm.nih.gov/pubmed/28548075 http://dx.doi.org/10.3390/biomedicines2040345 |
Ejemplares similares
-
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018) -
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015) -
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016) -
Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018) -
Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)